BioAge Labs (BIOA) Receivables - Net (2025 - 2026)
BioAge Labs (BIOA) posted Receivables - Net of $709000.0 for Q1 2026, down 7.8% sequentially from $769000.0 in Q4 2025, and up 96.4% YoY from $361000.0 in Q1 2025.
BioAge Labs (BIOA) Receivables - Net (2025 - 2026) Analysis & Trends
BioAge Labs has reported Receivables - Net for 2 years, with the latest figure at $709000.0 in Q1 2026.
- Quarterly Receivables - Net rose 96.4% year-over-year to $709000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $709000.0 (up 96.4% YoY) and the FY2025 annual result came in at $769000.0, changed N/A from the prior year.
- Receivables - Net retreated to $709000.0 in Q1 2026 per BIOA's latest filing, from $769000.0 in the prior quarter.
- Over five years, Receivables - Net peaked at $769000.0 in Q4 2025 and troughed at $361000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | BioAge Labs | 436.28 Mn | 436.28 Mn | -14.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 625,000.00 |
| Jun 30, 2026 | 625,000.00 |
| Mar 31, 2026 | 709,000.00 |
| Mar 31, 2026 | 709,000.00 |
| Dec 31, 2025 | 769,000.00 |
| Dec 31, 2025 | 769,000.00 |
| Sep 30, 2025 | 515,000.00 |
| Sep 30, 2025 | 515,000.00 |
| Jun 30, 2025 | 603,000.00 |
| Jun 30, 2025 | 603,000.00 |
| Mar 31, 2025 | 361,000.00 |
| Mar 31, 2025 | 361,000.00 |